Bayer HealthCare Marks 2010 World Hemophilia Day with EUR 250,000 Contribution
- Details
- Category: Bayer
To mark World Hemophilia Day, Bayer HealthCare is reaffirming its commitment to the global hemophilia community by pledging EUR 250,000 to the World Federation of Hemophilia (WFH).
Novo Nordisk launches international survey into the psychosocial effects of living with haemophilia
- Details
- Category: Novo Nordisk
Novo Nordisk announced today the start of a global survey into the psychological and social effects of haemophilia. The study, named HERO (Haemophilia Experiences, Results and Opportunities), will assess factors such as the attitudes of patients and their families to diagnosis and treatment, their aspirations and the social context of haemophilia.
Long-term efficacy and tolerability of Vimpat® (lacosamide)
- Details
- Category: Clinical Trials
UCB's antiepileptic drug (AED) Vimpat® (lacosamide) featured in several studies and analyses presented at the 62nd annual American Academy of Neurology (AAN) meeting. These data offer additional clinical evidence supporting the use of lacosamide as adjunctive therapy in the treatment of adult patients with partial-onset seizures.
Stemgent and Pfizer Announce Collaboration
- Details
- Category: Pfizer
Stemgent, Inc. and Pfizer Inc. (NYSE: PFE) announced a collaboration and research licensing agreement that will lead to certain research reagents developed or discovered by Pfizer being made available to the global research community through Stemgent.
Roche acquires Medingo Ltd. and expands its position in the growing insulin delivery systems market
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) and Elron Electronics Ltd. (TASE:ELRN) have signed an agreement under which Roche will acquire 100% of Medingo Ltd., a majority-owned subsidiary of the Elron group.
Additional Alemtuzumab Mechanism of Action Data Reported
- Details
- Category: Genzyme
Genzyme Corporation (Nasdaq: GENZ) reported four-year follow-up data from its completed Phase 2 multiple sclerosis (MS) trial showing an estimated 71 percent of alemtuzumab treated patients remain free of clinically-active disease as much as three years after most patients received their last course of the investigational compound.
A potential first-in-class, once-daily oral therapy for relapsing forms of multiple sclerosis
- Details
- Category: Novartis
Data from the two-year FREEDOMS study showed that Gilenia* 0.5 mg reduced annual relapse rates (ARR) by 62% for treatment naïve patients compared to placebo. For patients previously receiving other treatments, the annual relapse rates were reduced by 44%.
More Pharma News ...
- Sanofi-aventis and CureDM Sign Exclusive Worldwide License Agreement
- Nycomed and Baxter receive FDA approval for TachoSil®
- Novel agent Lu AE04621 enters Lundbeck's development pipeline
- Boehringer Ingelheim launches Global Venture Fund to foster innovation in life sciences
- GSK and Isis Pharmaceuticals collaborate on RNA therapeutics
- Pfizer Posts Details About Interactions With U.S. Physicians
- Novo Nordisk Introduces New Industry Resource for Information on Diabetes and Chronic Disease